Symberix
Pre-clinicalSymberix develops small molecule drugs targeting the gut microbiome to treat diseases without disrupting beneficial bacteria.
Founded
2016
Focus
MicrobiomeSmall Molecules
About
Symberix develops small molecule drugs targeting the gut microbiome to treat diseases without disrupting beneficial bacteria.
Funding History
2Total raised: $2.5M
Grant$500KNIHJun 15, 2019
Seed$2MUndisclosedJun 15, 2017
Company Info
TypePrivate
Founded2016
LocationDurham, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile